Infusion therapy claims carry some of the highest per-encounter values in outpatient billing. A biologic for rheumatoid arthritis, a chemotherapy regimen, or a hydration visit can represent hundreds to several thousand dollars per encounter, which makes the denial stakes correspondingly high. Despite that, the same four patterns account for most failures: J-code and drug administration code mismatches, site-of-care restrictions, step therapy failures, and prior authorization gaps. Knowing which pattern you are dealing with before you respond determines whether the appeal succeeds.
J-codes and drug administration code errors
J-codes identify the specific drug administered. Drug administration codes (96365 through 96417 for most commercial payers) identify how it was given: initial infusion, sequential infusion, concurrent infusion, or push injection. Both must be correct, and errors in each category produce different denial codes.
The most common J-code denial is not a wrong drug code. It is a mismatch between the drug quantity billed and the dose documented in the clinical record. Payers cross-reference the submitted units against the drug ordered and administered in the chart. A rounding difference, a wrong unit (billing per 10 mg when the code is per 1 mg), or a quantity that does not match the order produces a denial. Fix: pull the medication administration record, confirm the units, and submit a corrected claim.
Drug administration code errors are a separate problem. CO-97 fires when the administration sequence is billed incorrectly, for example two initial infusion codes (96365) instead of one initial code and a sequential code (96366). The fix is almost always a corrected claim with the right sequence, not a formal appeal.
Site-of-care denials
Commercial payers have increasingly issued site-of-care restrictions for certain biologics. The denial reads, in effect, that the drug is covered only in a lower-cost setting (home infusion or a payer-approved outpatient infusion suite) and not in the office. A CO-50 medical-necessity denial and a site-of-care denial can look similar on the remittance, but they require completely different appeals.
A site-of-care restriction is a coverage decision, not a clinical one. An appeal arguing clinical appropriateness does not address the payer's actual objection. A viable appeal argues one of two things: the patient has a documented clinical reason making the preferred site medically inappropriate (a prior adverse event in a home setting, an acute-care condition requiring on-site physician supervision, or a contraindication documented in the record), or the practice's setting qualifies as an approved site under the plan's own criteria. Request the plan's clinical coverage policy for the drug before writing the appeal.
If neither argument applies, the practical resolution is a site change going forward. Appealing on convenience or scheduling grounds rarely overturns a true site-of-care restriction.
Step therapy requirements
Step therapy requires documented evidence that the patient tried and failed one or more prior agents before a requested biologic will be covered. Denials here come in as CO-50 or as a prior authorization denial with a step therapy reason. The argument is the same for both: specific documented failure, not a general clinical preference.
- Name each prior agent specifically. Generic name, dose, duration, and the specific reason for discontinuation: inadequate response after how many weeks, an adverse event of what type, or a documented contraindication.
- Use dates. Payers compare the documentation against their own step therapy criteria, which typically require a minimum duration of prior therapy (often 3 to 6 months). Vague language like "patient failed methotrexate" without dates will not satisfy the criteria.
- Request the plan's clinical policy. Step therapy criteria vary by payer and by drug class. The specific agent list and duration requirement is in the plan's coverage document. You are entitled to it, and knowing exactly what the criteria say prevents appealing against criteria you have not seen.
Prior authorization gaps
Biologics and many chemotherapy agents require prior authorization from essentially every commercial payer. CO-15 fires when the authorization was not obtained before the infusion. In Texas, retroactive authorization is possible with some payers but far from guaranteed.
For infusion claims denied for missing auth, the options narrow quickly: retroactive auth request with documentation of why the service was urgent or why the auth window closed; a peer-to-peer review with the payer's medical director; or a formal appeal with the treating physician's documented rationale attached. None of these is a reliable recovery path. Prevention, meaning authorization confirmed before the first infusion date, is the only clean answer for this category.
Why the appeal economics work here
Infusion denials are worth working more consistently than most small-dollar denial categories because per-claim values are high enough that a manual appeal is cost-effective at almost any claim size above $50. The challenge is matching the right argument to the right denial type. A site-of-care response sent for a J-code quantity error gets ignored; a medical-necessity argument sent for a step therapy denial misses the payer's actual objection.
Triage by denial type before drafting anything. Pull the RARC on the 835 line, check the clinical record for the specific issue the RARC identifies, and then route: corrected claim for J-code and administration code errors, coverage argument for site-of-care, clinical documentation for step therapy, and the authorization process for CO-15. Each path is distinct and each produces better results when you stay in its lane.
For the broader medical-necessity appeal process, including how AI drafting tools handle the first-draft clinical argument, and for context on the revenue leakage these denials feed into when left unworked, see the linked guides.